The clinical success of ADCs has redefined HER2-low BC as a distinct therapeutic entity, prompting ongoing efforts to refine patient selection and optimize treatment combinations, including integration with immunotherapy [174]. The gene discussed is ERBB2; the disease is breast cancer.